MEK and the inhibitors: from bench to bedside

Akintunde Akinleye; Muhammad Furqan; Nikhil Mukhi; Pavan Ravella; Delong Liu

doi:10.1186/1756-8722-6-27

MEK and the inhibitors: from bench to bedside

J Hematol Oncol. 2013 Apr 12:6:27. doi: 10.1186/1756-8722-6-27.

Authors

Akintunde Akinleye¹, Muhammad Furqan, Nikhil Mukhi, Pavan Ravella, Delong Liu

Affiliation

¹ Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY 10595, USA. DELONG_LIU@NYMC.EDU.

Abstract

Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of metastatic melanoma with BRAF V600 mutation. Selumetinib has been studied in combination with docetaxel in phase II randomized trial in previously treated patients with advanced lung cancer. Selumetinib group had better response rate and progression-free survival. This review also summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162 (ARRY 438162), RO5126766, WX-554, RO4987655 (CH4987655), GDC-0973 (XL518), and AZD8330.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Humans
MAP Kinase Kinase 1 / antagonists & inhibitors*
Neoplasms / drug therapy*
Protein Kinase Inhibitors / therapeutic use*

Substances

Protein Kinase Inhibitors
MAP Kinase Kinase 1